Erlangen University Joins Prestigious Team of BSD-2000 Based Hyperthermia Treatment Centers

Apr 11, 2001, 01:00 ET from BSD Medical Corp.

    SALT LAKE CITY, April 11 /PRNewswire/ -- BSD Medical Corp.
 (OTC Bulletin Board:   BSDM) today announced that the University Medical School
 of Erlangen, Germany has ordered a BSD-2000/3D system, joining the community
 of prestigious institutions around the world at the forefront of research in
 hyperthermic oncology using the equipment of choice, the BSD-2000 hyperthermia
 system.  Other internationally-known hyperthermia treatment centers within
 this network of BSD-2000 users include Duke University Medical Center,
 Northwestern University Medical School, University of Southern California,
 Centennial Medical Center, Daniel den Hoed Cancer Center of the Academisch
 Ziekenhuis (Rotterdam, The Netherlands), Haukeland University Hospital
 (Bergen, Norway), Dusseldorf University Medical School, Tubingen University
 Medical School, Essen University Hospital, Charite Medical School of Humboldt
 University (Berlin), Luebeck University Medical School, Munich University
 Medical School Grosshadern, Interne Klinik Argirov of the Munich Comprehensive
 Cancer Center (all of Germany), University of Verona Medical Center (Italy),
 Graz University Medical School (Austria) and Kantonsspital Aarau
 (Switzerland).
     These international cancer treatment centers are well known for their
 scientific credentials.  For example, a 358 patient phase III clinical trial
 from Daniel den Doed Cancer Center in Rotterdam was published last year in THE
 LANCET, the world's longest running medical journal.  The study involving the
 BSD-2000 reported that for advanced cervical cancer complete response
 (disappearance of the tumor) increased by 46% when hyperthermia was added to
 radiation therapy, and survival after three years improved by 89% with the
 additive benefit of hyperthermia therapy.
     The Radiotherapy Department of the University Medical School at Erlangen
 is undergoing an expansion, and BSD 's premium hyperthermia system, the
 BSD-2000/3D, will be installed in late 2001 in their new hyperthermia suite.
 The roomy suite has a lavish layout of 1,100 square feet and is positioned
 next door to one of the new linear accelerator suites, allowing the timely
 sequencing of radiotherapy and hyperthermia treatment fractions.  Professor
 Rolf Sauer, head of the department and editor in chief of the world's longest
 running radiotherapy-dedicated scientific review, Strahlentherapie, has been
 running clinical hyperthermia programs in his department for more than
 15 years.  Professor Gebauer, substitute department head, recently stated
 publicly that the intention at Erlangen is to become one of the foremost
 clinical treatment sites for deep regional hyperthermia in Germany, and the
 BSD-2000/3D suites this purpose perfectly.
 
     BSD Medical is the leading developer of hyperthermia equipment for
 treating cancer, including tumors located deep in the body.  The BSD-2000
 attacks deep tumors using microwaves focused through technology like that used
 in deep space radio telescopes.   Deep hyperthermia is highly desirable as a
 cancer treatment because it is non-toxic and non-invasive.  To learn more
 about this revolutionary new cancer therapy, visit the BSD website at
 www.bsdmc.com.
 
     Statements contained in this press release that are not historical facts
 are forward looking statements, as that item is defined in the Private
 Securities Litigation Reform Act of 1995.  Such forward-looking statements are
 subject to risks and uncertainties (detailed in the Company's filings with the
 Securities and Exchange Commission) that could cause actual results to differ
 materially from estimated results.
 
 

SOURCE BSD Medical Corp.
    SALT LAKE CITY, April 11 /PRNewswire/ -- BSD Medical Corp.
 (OTC Bulletin Board:   BSDM) today announced that the University Medical School
 of Erlangen, Germany has ordered a BSD-2000/3D system, joining the community
 of prestigious institutions around the world at the forefront of research in
 hyperthermic oncology using the equipment of choice, the BSD-2000 hyperthermia
 system.  Other internationally-known hyperthermia treatment centers within
 this network of BSD-2000 users include Duke University Medical Center,
 Northwestern University Medical School, University of Southern California,
 Centennial Medical Center, Daniel den Hoed Cancer Center of the Academisch
 Ziekenhuis (Rotterdam, The Netherlands), Haukeland University Hospital
 (Bergen, Norway), Dusseldorf University Medical School, Tubingen University
 Medical School, Essen University Hospital, Charite Medical School of Humboldt
 University (Berlin), Luebeck University Medical School, Munich University
 Medical School Grosshadern, Interne Klinik Argirov of the Munich Comprehensive
 Cancer Center (all of Germany), University of Verona Medical Center (Italy),
 Graz University Medical School (Austria) and Kantonsspital Aarau
 (Switzerland).
     These international cancer treatment centers are well known for their
 scientific credentials.  For example, a 358 patient phase III clinical trial
 from Daniel den Doed Cancer Center in Rotterdam was published last year in THE
 LANCET, the world's longest running medical journal.  The study involving the
 BSD-2000 reported that for advanced cervical cancer complete response
 (disappearance of the tumor) increased by 46% when hyperthermia was added to
 radiation therapy, and survival after three years improved by 89% with the
 additive benefit of hyperthermia therapy.
     The Radiotherapy Department of the University Medical School at Erlangen
 is undergoing an expansion, and BSD 's premium hyperthermia system, the
 BSD-2000/3D, will be installed in late 2001 in their new hyperthermia suite.
 The roomy suite has a lavish layout of 1,100 square feet and is positioned
 next door to one of the new linear accelerator suites, allowing the timely
 sequencing of radiotherapy and hyperthermia treatment fractions.  Professor
 Rolf Sauer, head of the department and editor in chief of the world's longest
 running radiotherapy-dedicated scientific review, Strahlentherapie, has been
 running clinical hyperthermia programs in his department for more than
 15 years.  Professor Gebauer, substitute department head, recently stated
 publicly that the intention at Erlangen is to become one of the foremost
 clinical treatment sites for deep regional hyperthermia in Germany, and the
 BSD-2000/3D suites this purpose perfectly.
 
     BSD Medical is the leading developer of hyperthermia equipment for
 treating cancer, including tumors located deep in the body.  The BSD-2000
 attacks deep tumors using microwaves focused through technology like that used
 in deep space radio telescopes.   Deep hyperthermia is highly desirable as a
 cancer treatment because it is non-toxic and non-invasive.  To learn more
 about this revolutionary new cancer therapy, visit the BSD website at
 www.bsdmc.com.
 
     Statements contained in this press release that are not historical facts
 are forward looking statements, as that item is defined in the Private
 Securities Litigation Reform Act of 1995.  Such forward-looking statements are
 subject to risks and uncertainties (detailed in the Company's filings with the
 Securities and Exchange Commission) that could cause actual results to differ
 materially from estimated results.
 
 SOURCE  BSD Medical Corp.